NanoViricides Advances Broad-Spectrum Antiviral NV-387 Toward Phase II Trials for MPox in DRC
NanoViricides' quarterly report details progress with NV-387, including regulatory approval for Phase II MPox trials in the DRC and FDA orphan drug designation for measles, highlighting its broad-spectrum antiviral strategy.
NanoViricides, Inc. (NYSE American: NNVC) has reported significant advancements in its antiviral pipeline, particularly for its lead candidate NV-387, as detailed in the company's quarterly report for the period ended March 31, 2026. The company has obtained regulatory approval to initiate Phase II clinical development for MPox in the Democratic Republic of Congo, marking a critical step toward addressing a disease that continues to pose public health challenges in the region.
Beyond MPox, NanoViricides is pursuing an orphan-first regulatory strategy that has already yielded results. Subsequent to the quarter, the U.S. Food and Drug Administration granted orphan drug designation for NV-387 as a treatment for measles, with additional applications targeting MPox and smallpox under review. This approach aims to leverage the benefits of orphan status, including development incentives and market exclusivity, to accelerate the path to approval for these viral indications.
The company's platform technology, based on TheraCour nanomedicine, enables the creation of broad-spectrum antiviral drugs. NV-387 is being developed not only for MPox but also for respiratory viral infections such as RSV, COVID-19, Long COVID, influenza, and even measles. The drug candidate NV-CoV-2 (API NV-387) targets COVID-19 directly, while NV-CoV-2-R encapsulates remdesivir within its polymeric micelles, potentially offering an improved treatment option given remdesivir's existing FDA approval.
The importance of NanoViricides' progress lies in the urgent need for effective treatments against viruses that have limited therapeutic options. MPox, which caused global outbreaks in 2022-2023, continues to affect populations in Africa, and the DRC has experienced recurring cases. An effective antiviral could significantly reduce disease severity and transmission. Similarly, measles remains a major cause of child mortality in developing countries, and an orphan-designated drug could provide a new tool for treatment, especially in outbreak settings.
However, the company acknowledges the inherent risks in drug development. As noted in the report, "the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital." There is no assurance that NV-387 or any of the company's candidates will prove safe and effective in clinical trials or reach the market.
NanoViricides also has a broad pipeline targeting other viral diseases, including herpes, influenza, HIV, hepatitis C, rabies, dengue, and Ebola. The company's business model relies on licensing technology from TheraCour Pharma, Inc. for specific viral applications, which it has done since its founding in 2005.
For investors and stakeholders, the quarterly report provides a snapshot of the company's strategic focus on advancing NV-387 through clinical development while expanding its orphan drug portfolio. The full press release is available at https://ibn.fm/osO0q and the company's newsroom at https://ibn.fm/NNVC.